Vaccination News

Following the FDA’s authorization and CDC’s recommendation of bivalent COVID-19 booster vaccines, U.S. officials said that Americans will likely need annual COVID-19 vaccine doses, similar to influenza.

People who were pregnant or lactating when they received a booster or third dose of the COVID-19 vaccine tolerated it well, according to the results of a prospective cohort study published in JAMA Network Open.

Researchers reported more promising data on a malaria vaccine that previously demonstrated high efficacy among children aged 5 to 17 months in a study published last year.

Experts raised questions about comments from U.S. officials this week that the new bivalent COVID-19 boosters are likely the first of what will become annual shots against SARS-CoV-2.

Parental concern about the safety of childhood vaccines increased significantly during the first 2 years of the COVID-19 pandemic, although confidence in vaccines remained high, according to research published in Pediatrics.

Last week, the FDA authorized bivalent COVID-19 booster vaccines for emergency use in the United States.

The CDC’s vaccine advisory committee on Thursday voted to recommend the bivalent COVID-19 booster vaccines authorized this week by the FDA that also target the omicron variant of SARS-CoV-2.

As of Aug. 5, approximately half of all eligible Americans aged 5 years or older had received their first COVID-19 booster vaccine, according to data published Thursday in MMWR.

Researchers in Denmark announced the successful completion of an “innovative” trial assessing effects of influenza vaccine dosages on hospitalizations using only routinely collected data.

The FDA on Wednesday authorized bivalent COVID-19 booster vaccines from Moderna and Pfizer-BioNTech for emergency use in the United States.